An interventional study of Cognitive Behavioral Therapy (CBT4CBT) in Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate and Cannabis Use Disorder, Severe, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.
Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 118th largest by enrollment of the 1,017 interventional ones that give a count, is one of 42 that started in 2021, is one of 119 with no phase, and was the 1,000th registered.
1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 18–80
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 501 · Phase 2 523 · Phase 3 113 · Phase 4 11
First in 1988; this study’s year is marked. 42 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 38 across the 1,017 interventional studies, 74 across the 62 observational. Of the 904 that completed or were terminated, 358 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
346 of 1,187 have an industry lead sponsor. The 10 most frequent:
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Medical University of South Carolina has 2 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
68 of the studies in Lymphoma, Follicular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT00659035Asokumar BuvanendranUse of Driving Tests to Evaluate Patient Performance on Oral Opioids | 2026-12 |
| NCT06245031Cognito Therapeutics, Inc.Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) | 2026-12 |
Add all 68 to your calendar (.ics) → With an account.
Among the 1,187 studies in Lymphoma, Follicular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
112 male participants were enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They received a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist.
Behavioral: Cognitive Behavioral Therapy (CBT4CBT)
112 female participants were enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They received a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist.
Behavioral: Cognitive Behavioral Therapy (CBT4CBT)
Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Proportion of Participants in Remission
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
Time frame: Week 4
Proportion of Participants in Remission
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
Time frame: Week 8
Proportion of Participants in Remission
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
Time frame: Week 12
Proportion of Participants in Remission
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
Time frame: Week 16
Proportion of Participants in Remission
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
Time frame: Week 20
Reduction in Cannabis Use Days
Number of cannabis use days assessed via daily diaries during treatment, past 28 days
Time frame: 8 weeks of treatment
Reduction in Cannabis Use Episodes
Number of cannabis use grams assessed via daily diaries during treatment, last 28 days
Time frame: 8 weeks of treatment
| Milestone | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Started | 112 | 112 |
| Week 4 | 91 | 94 |
| Week 8 | 86 | 89 |
| Week 12 | 82 | 82 |
| Week 16 | 79 | 81 |
| Completed | 78 | 79 |
| Not completed | 34 | 33 |
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
| Participants | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Proportion of Participants in Remission | 5 | 2 |
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
| Participants | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Proportion of Participants in Remission | 18 | 9 |
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
| Participants | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Proportion of Participants in Remission | 21 | 9 |
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
| Participants | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Proportion of Participants in Remission | 17 | 14 |
Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.
| Participants | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Proportion of Participants in Remission | 25 | 20 |
Number of cannabis use days assessed via daily diaries during treatment, past 28 days
| days | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Reduction in Cannabis Use Days | 21.0 ± 9.1 | 21.4 ± 6.8 |
Number of cannabis use grams assessed via daily diaries during treatment, last 28 days
| grams | Cognitive Behavioral Therapy - Men | Cognitive Behavioral Therapy - Women |
|---|---|---|
| Reduction in Cannabis Use Episodes | 22.3 ± 28.9 | 15.6 ± 16.5 |
Collected over Adverse events are collected beginning as study enrollment until the end of follow-up at week 20.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cognitive Behavioral Therapy - Males | 0/112 (0%) | 0/112 (0%) | 27/112 (24.1%) |
| Cognitive Behavioral Therapy - Females | 0/112 (0%) | 1/112 (0.9%) | 36/112 (32.1%) |
| Event | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| SinusitisInfections and infestations | 0/112 | 1/112 |
| Event | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females |
|---|---|---|
| Viral Upper Respiratory Tract InfectionsInfections and infestations | 16/112 | 21/112 |
| sore throatInfections and infestations | 4/112 | 8/112 |
| Nasal CongestionInfections and infestations | 5/112 | 8/112 |
| Influenza Like IllnessInfections and infestations | 6/112 | 6/112 |
| Age, Continuous(years) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| Mean | 32.6 ± 11 | 30.2 ± 11.6 | 31.4 ± 11.3 |
| Sex: Female, Male(Participants) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| Female | 0 | 112 | 112 |
| Male | 112 | 0 | 112 |
| Race (NIH/OMB)(Participants) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 18 | 38 |
| White | 80 | 81 | 161 |
| More than one race | 5 | 10 | 15 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 9 | 18 |
| Not Hispanic or Latino | 103 | 103 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| United States | 112 | 112 | 224 |
| Grams of Cannabis use(grams) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| Mean | 63.4 ± 178.3 | 47.6 ± 57 | 54.9 ± 132.2 |
| Cannabis Use Days(days) | Cognitive Behavioral Therapy - Males | Cognitive Behavioral Therapy - Females | Total |
|---|---|---|---|
| Mean | 26.2 ± 6.5 | 26.7 ± 5.7 | 26.3 ± 6.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Investigators support data sharing as essential for scientific advancement. It is expected that primary outcome papers will be completed and submitted to appropriate peer-reviewed scientific journals within 180 days of data lock. Requests for data from this project by individuals outside of the research team will be reviewed by the team following data lock. Data sharing will adhere to all provisions of the Health Insurance Portability and Accountability Act (HIPAA) and the rights and privacy of people who participate in research will be protected at all times. The requesting Investigator must specify the subset of variables needed or provide a detailed justification of why the complete dataset is absolutely necessary. Data made available to other investigators will be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects.
Supporting information: Study protocol, Informed consent form
Time frame: Requests for data from this project by individuals outside of the research team will be reviewed by the team 180 days after study completion.
Access criteria: The requesting Investigator must specify the subset of variables needed. Data made available to other investigators will be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects. Data will be shared via CSV file or other requested formats, if the study team is able to accommodate the alternative requested format.
Ran from Nov 2021 to primary completion in Oct 2025, 47 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 143 non-industry interventional studies with no phase under Lymphoma, Follicular, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 47. This study's 47 months is above that.
Counting every sponsor, half of 167 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →